mrna-4157,pembrolizumab
merck,moderna
['mrna-4157', 'pembro']
the recurrence-free survival was 78.6% among patients treated with mrna-4157/v940 plus pembrolizumab and 62.2% among those treated with pembrolizumab alone, corresponding to a 44% reduction in the risk of recurrence or death. #aacr23
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration.